PRESERFLO™ MicroShunt Implantation in Patients with Primary Open-Angle Glaucoma: 10-Year Results from a Single-Center Nonrandomized Study
Main Article Content
Abstract
Intraocular implantation of the PRESERFLOTM MicroShunt has been shown to be effective in lowering intraocular pressure in patients with primary open-angle glaucoma. A single-site, open-label study in the Dominican Republic (NCT00772330) found that MicroShunt implantation resulted in sustained reductions in mean intraocular pressure and glaucoma medications after 1, 3 and 5 years, with no long-term sight-threatening adverse events and with low rates of post-operative interventions. The present study reports results in these patients after 10 years.
The original trial included patients aged 18–85 years with primary open-angle glaucoma inadequately controlled on maximum tolerated medical therapy, with medicated intraocular pressure ranging from 18–40 mmHg, who underwent monocular MicroShunt implantation. Patients who remained in this trial after 10 years, were included. The primary safety endpoint was the incidence of all device- and/or procedure-related adverse events. Secondary endpoints included the mean intraocular pressure and mean reduction in intraocular pressure from baseline, the mean number of glaucoma medications and changes in visual field.
Of the 23 patients initially enrolled in this trial, nine remained after 10 years. Mean medicated intraocular pressure in operated eyes was lower at 10 years than at baseline, with mean percent reductions in intraocular pressure being greater in operated than in non-operated eyes throughout the 10-year period. Glaucoma medication use returned to baseline after 10 years, with none of the nine patients being medication-free. Relative to endothelial cell counts at 5 years, endothelial cell counts at 10 years showed a greater decrease in non-operated than in operated eyes. The percentages of eyes with bullae began to decrease after 1 year, with 67% of eyes having bullae after 10 years. The mean deviation of change in visual field was stable for 36 months, but showed increasing variability thereafter.
The present study showed that the PRESERFLOTM MicroShunt is an effective and safe long-term option for the surgical management of primary open-angle glaucoma in this study population. Prospective clinical trials are needed to compare the long-term efficacy and safety of MicroShunt implantation with other treatments, such as trabeculectomy.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. Lancet. 2017;390(1010 8):2183–2193. doi: 10.1016/S0140-6736(17)31469-1
3. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90(3):262–267. doi: 10.1136/ bjo.2005.081224
4. Flaxman SR, Bourne RRA, Resnikoff S, et al; Vision Loss Expert Group of the Global Burden of Disease Study. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(12):e1221–e1234. doi: 10.1016/S2 214-109X(17)30393-5
5. Mantravadi AV, Vadhar N. Glaucoma. Prim Care. 2015;42(3):437–449. doi: 10.1016/j.pop.2015.05.008
6. Gedde SJ, Vinod K, Wright MM, et al; American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel. Primary open-angle glaucoma preferred practice pattern. Ophthalmology. 2021; 128(1):P71–P150. doi: 10.1016/j.ophtha.2020.10.022
7. European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options. Br J Ophthalmol. 2017;101(6):130–195. doi: 10.1136/bjophthalmol-2016-EGSguideline.003
8. Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL; Tube versus Trabeculectomy Study Group. Treatment outcomes in the tube versus trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol. 2012;153(5):789–803. doi: 10.1016/j. ajo.2011.10.026
9. Gedde SJ, Feuer WJ, Lim KS, et al; Primary Tube versus Trabeculectomy Study Group. Treatment outcomes in the primary tube versus trabeculectomy study after 5 years. Ophthalmology. 2022;129(12): 1344–1356. doi: 10.1016/j.ophtha.2022.07.003
10. Richter GM, Coleman AL. Minimally invasive glaucoma surgery: current status and future prospects. Clin Ophthalmol. 2016;10:189–206. doi: 10.2147/OPTH.S80490
11. Saheb H. Ahmed II. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol. 2012;23(2):96–104. doi: 10.1097/ICU.0b013e32834ff1e7
12. Pinchuk L, Riss I, Batlle JF, et al. The development of a micro-shunt made from poly(styrene-block-isobutylene-block-styrene) to treat glaucoma. J Biomed Mater Res B Appl Biomater. 2017;105(1): 211–221. doi: 10.1002/jbm.b.33525
13. Baker ND, Barnebey HS, Moster MR, et al; INN005 Study Group. Ab-externo microshunt versus trabeculectomy in primary open-angle glaucoma: One-year results from a 2-year randomized, multicenter study. Ophthalmology. 2021;128(12): 1710–1721. doi: 10.1016/j.ophtha.2021.05.023
14. Panarelli JF, Moster MR, Garcia-Feijoo J, et al.; INN005 Study Group. Ab-externo microshunt versus trabeculectomy in primary open-angle glaucoma: Two-year results from a randomized, multicenter study. Ophthalmology. 2024;131(3):266–276. doi: 10.1016/j.ophtha.2023.09.023
15. Fili S, Kontopoulou K, Vastardis I, Perdikakis G, Kohlhaas M. PreserFlo™ MicroShunt versus trabeculectomy in patients with moderate to advanced open-angle glaucoma: 12-month follow-up of a single-center prospective study. Cureus. 2022;14(8):e28288. doi: 10.7759/cureus.28288
16. Pillunat KR, Herber R, Haase MA, Jamke M, Jasper CS, Pillunat LE. PRESERFLO™ MicroShunt versus trabeculectomy: first results on efficacy and safety. Acta Ophthalmol. 2022;100(3):e779-e790. doi: 10.1111/aos.14968
17. Fu MX, Normando EM, Luk SMH, et al. MicroShunt versus trabeculectomy for surgical management of glaucoma: a retrospective analysis. J Clin Med. 2022;11(18):5481. doi: 10.339 0/jcm11185481
18. Riss I. A 2-year, single-center study to assess the safety and effectiveness of the MicroShunt in primary open-angle glaucoma. Ophthalmic Res. 2023;66(1):206–217. doi: 10.1159/000526960
19. Beckers HJM, Aptel F, Webers CAB, et al. Safety and effectiveness of the PRESERFLO microshunt in primary open-angle glaucoma: Results from a 2-year multicenter study. Ophthalmol Glaucoma. 2022;5(2):195–209. doi: 10.1016/j.ogla.2021.07.008
20. Batlle JF, Fantes F, Riss I, et al. Three-year follow-up of a novel aqueous humor MicroShunt. J Glaucoma. 2016;25(2):e58–e65. doi: 10.1097/IJG. 0000000000000368
21. Batlle JF, Corona A, Albuquerque R. Long-term results of the PRESERFLO MicroShunt in patients with primary open-angle glaucoma from a single-center nonrandomized study. J Glaucoma. 2021;30 (3):281–286. doi: 10.1097/IJG.0000000000001734
22. Wilkins MR, Occleston NL, Kotecha A, Waters L, Khaw PT. Sponge delivery variables and tissue levels of 5-fluorouracil. Br J Ophthalmol. 2000;84 (1):92¬–97. doi: 10.1136/bjo.84.1.92
23. Dhingra S, Khaw PT. The moorfields safer surgery system. Middle East Afr J Ophthalmol. 2009;16(3): 112¬–115. doi: 10.4103/0974-9233.56220
24. Crowston JG, Wang XY, Khaw PT, Zoellner H, Healey PR. Human serum reduces mitomycin-C cytotoxicity in human Tenon’s fibroblasts. Invest Ophthalmol Vis Sci. 2006;47(3):946–952. doi: 10. 1167/iovs.05-1048
25. Al Habash A, Aljasim LA, Owaidhah O, Edward DP. A review of the efficacy of mitomycin C in glaucoma filtration surgery. Clin Ophthalmol. 2015;9:1945¬–1951. doi: 10.2147/OPTH.S80111
26. Garcia-Feijoo J, Batlle JF, Aptel F, et al. Pooled analysis of three MicroShunt studies in primary open-angle glaucoma evaluating different concentrations of applied mitomycin C.Ophthalmol Ther. 2025, in press. doi: 10.1007/s40123-025-01149-4
27. Pinchuk L. Development of SIBS and the PRESERFLO™ MicroShunt to treat advanced glaucoma: a review. Med Res Arch. 2025;13(2):61 69. doi: 10.18103/mra.v13i2.6169
28. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107(1):38-42. doi: 10.1161/01.cir. 0000047700.58683.a1.